P-43 Randomised phase III trial of docetaxel/carboplatin vs. MIC/MVP chemotherapy in inoperable Advanced non-small cell lung cancer (NSCLC) — Do XPD polymorphisms predict for sensitivity or resistance to platinum based chemotherapy

✍ Scribed by Booton, Richard; Campbell, Daniel; Ward, Tim; Ashcroft, L.; Power, Fiona; Taylor, Pat; Burt, Paul; Wierenga, Gilbert; Thathcer, Nicholas

• Book ID: 118571744
• Publisher: Elsevier Science
• Year: 2003
• Tongue: English
• Weight: 348 KB
• Volume: 41
• Category: Article
• ISSN: 0169-5002
• DOI: 10.1016/s0169-5002(03)92012-5